Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Burning Rock Biotech Limited (BNR)

2.48   0.19 (8.3%) 11-28 16:00
Open: 2.32 Pre. Close: 2.29
High: 2.52 Low: 2.27
Volume: 102,112 Market Cap: 262(M)

Technical analysis

as of: 2022-11-28 4:38:22 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 3.49     One year: 4.07
Support: Support1: 2.19    Support2: 1.7
Resistance: Resistance1: 2.99    Resistance2: 3.49
Pivot: 2.22
Moving Average: MA(5): 2.33     MA(20): 2.17
MA(100): 2.81     MA(250): 5.3
MACD: MACD(12,26): 0     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 45.9     %D(3): 42.5
RSI: RSI(14): 60.4
52-week: High: 14  Low: 1.7
Average Vol(K): 3-Month: 321 (K)  10-Days: 224 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ BNR ] has closed below upper band by 11.9%. Bollinger Bands are 30.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.52 - 2.53 2.53 - 2.55
Low: 2.24 - 2.25 2.25 - 2.27
Close: 2.46 - 2.48 2.48 - 2.5

Company Description

Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. In addition, the company has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. It has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. The company was incorporated in 2014 and is headquartered in Guangzhou, China.

Headline News

Thu, 24 Nov 2022
Leonardo Badea (BNR): Financial education - strengthening the resilience of the population and financial stability in the context of overlapping crises - Business Review

Fri, 18 Nov 2022
In the wake of Brenntag SE's (ETR:BNR) latest €312m market cap drop, institutional owners may be forced to take severe actions - Simply Wall St

Wed, 16 Nov 2022
Economists weigh in on new BNR lending rate increase| The New Times - New Times Publication

Wed, 16 Nov 2022
Health Care Sector Update for 11/16/2022: ALC, DNA, BNR, XLV, IBB - Nasdaq

Wed, 16 Nov 2022
Burning Rock Biotech (BNR) Q3 2022 Earnings Call Transcript - Seeking Alpha

Tue, 15 Nov 2022
What is the Market's View on Burning Rock Biotech Ltd (BNR) Stock's Price and Volume Trends Tuesday? - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Diagnostics & Research
Shares Out. 106 (M)
Shares Float 45 (M)
% Held by Insiders 5.8 (%)
% Held by Institutions 58.4 (%)
Shares Short 1,870 (K)
Shares Short P.Month 1,940 (K)

Stock Financials

EPS -1.27
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 12.5
Profit Margin (%) -177.1
Operating Margin (%) -178.7
Return on Assets (ttm) -30.6
Return on Equity (ttm) -59.9
Qtrly Rev. Growth 22.1
Gross Profit (p.s.) 3.44
Sales Per Share 5.37
EBITDA (p.s.) -9.1
Qtrly Earnings Growth 0
Operating Cash Flow -501 (M)
Levered Free Cash Flow -452 (M)

Stock Valuations

PE Ratio -1.96
PEG Ratio -3.4
Price to Book value 0.19
Price to Sales 0.46
Price to Cash Flow -0.53

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.